| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Revenue | $2.0M | — |
| R&D Expense | $286K | -81.1% |
| SG&A Expense | $5.3M | -34.3% |
| Operating Income | -$3.6M | +72.0% |
| Pre-tax Income | -$3.1M | +41.9% |
| Income Tax | $0 | — |
| Net Income | -$3.1M | +41.9% |
| EPS (Basic) | -$1.21 | +46.2% |
| EPS (Diluted) | -$1.21 |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $3.2M | -57.3% |
| Accounts Receivable | $556K | — |
| Current Assets | $4.2M | -47.3% |
| Total Assets | $9.6M | -28.4% |
| Current Liabilities | $725K | -65.2% |
| Stockholders' Equity | $8.8M | -21.6% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$4.3M | +79.6% |
| Investing Cash Flow | $0 | -100.0% |
| Financing Cash Flow | $0 | -100.0% |
| +46.2% |